智通财经APP讯,维立志博-B(09887)发布公告,评价维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗,LBL-024)用于治疗一线食管鳞状细胞癌的II期临床研究首例患者已成功入组。
本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳院长牵头,正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线食管鳞状细胞癌患者的有效性和安全性。
智通财经APP讯,维立志博-B(09887)发布公告,评价维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗,LBL-024)用于治疗一线食管鳞状细胞癌的II期临床研究首例患者已成功入组。
本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳院长牵头,正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线食管鳞状细胞癌患者的有效性和安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.